Public Meeting: Patient-Focused Drug Development for Vitiligo

preview_player
Показать описание
On March 8, 2021, FDA hosted a public meeting on Patient-Focused Drug Development for Vitiligo. FDA was interested in obtaining patient perspectives on the health effects and daily impacts of vitiligo, treatment goals, and decision factors considered when seeking out or selecting a treatment. For more information, visit the meeting webpage.
  1. U.S. Food and Drug Administration
  2. “patient-focused drug development”
  3. PFDD
  4. drugs
  5. “drug development”
  6. vitiligo
Рекомендации по теме
Public Meeting: Patient-Focused 1:58:49

Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 1)

Public Meeting: Patient-Focused 3:58:26

Public Meeting: Patient-Focused Drug Development for Systemic Sclerosis

Public Meeting: Patient-Focused 1:32:12

Public Meeting: Patient-Focused Drug Development for Chagas Disease (Part 1 of 4)

Public Meeting: Patient-Focused 1:58:05

Public Meeting: Patient-Focused Drug Development for Fibromyalgia (Part 1 of 2)

Public Meeting: Patient-Focused 1:48:22

Public Meeting: Patient-Focused Drug Development for Huntington’s and Parkinson’s Disease (Part 1)...

Public Webinar: Patient-Focused 1:59:38

Public Webinar: Patient-Focused Drug Development Draft Guidance 4

Virtual Public Meeting 5:18:41

Virtual Public Meeting on Patient-Focused Drug Development for Long COVID

Public Meeting on 1:48:42

Public Meeting on Patient Focused Drug Development for Narcolepsy Part 2

PD 10 – 1:33:15

PD 10 – Driving Action: Innovation & Access for Resilient Responses Against AMR

Public Meeting: Patient-Focused 3:57:57

Public Meeting: Patient-Focused Drug Development for Vitiligo

Public Meeting on 2:07:05

Public Meeting on Patient Focused Drug Development for Narcolepsy Part 1

Public Meeting: Patient-Focused 1:54:32

Public Meeting: Patient-Focused Drug Development for Autism (Part 1 of 2)

Public Meeting: Patient-Focused 4:16:21

Public Meeting: Patient-Focused Drug Development for Stimulant Use Disorder

Public Meeting on 1:47:12

Public Meeting on Patient Focused Drug Development for Functional GI Disorders Part 2

Public Meeting on 1:48:56

Public Meeting on Patient Focused Drug Development for Non Tuberculous Mycobacterial Infections Pt 1

Public Meeting on 1:14:05

Public Meeting on Patient Focused Drug Development for Non Tuberculous Mycobacterial Infections Pt 2

Public Meeting: Patient-Focused 2:30:29

Public Meeting: Patient-Focused Drug Development for Hereditary Angioedema (Part 1 of 2)

Public Webinar: Patient-Focused 2:34:13

Public Webinar: Patient-Focused Drug Development Draft Guidance 3

Public Meeting on 1:59:53

Public Meeting on Patient Focused Drug Development for Functional GI Disorders Part 1

Public Meeting: Patient-Focused 2:18:58

Public Meeting: Patient-Focused Drug Development for Female Sexual Dysfunction (Part 1 of 2)

Public Meeting: Patient-Focused 1:49:05

Public Meeting: Patient-Focused Drug Development for Fibromyalgia (Part 2 of 2)

Public Meeting: Patient-Focused 2:36:58

Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 2)

Public Meeting: Patient-Focused 0:51:39

Public Meeting: Patient-Focused Drug Development for Neuropathic Pain (Part 2 of 3)

Public Meeting: Patient-Focused 2:44:46

Public Meeting: Patient-Focused Drug Development for Hemophilia A, B, & Other Bleeding Disorders...